Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte precursor cell | 8 studies | 26% ± 7% | |
GABAergic neuron | 8 studies | 38% ± 17% | |
interneuron | 6 studies | 35% ± 12% | |
retina horizontal cell | 6 studies | 26% ± 10% | |
Mueller cell | 6 studies | 49% ± 20% | |
epithelial cell | 5 studies | 22% ± 2% | |
neuron | 4 studies | 42% ± 19% | |
respiratory goblet cell | 4 studies | 42% ± 15% | |
goblet cell | 4 studies | 32% ± 23% | |
oligodendrocyte | 4 studies | 25% ± 4% | |
GABAergic interneuron | 3 studies | 26% ± 5% | |
astrocyte | 3 studies | 34% ± 3% | |
enteroendocrine cell | 3 studies | 29% ± 6% | |
glutamatergic neuron | 3 studies | 24% ± 6% | |
kidney distal convoluted tubule epithelial cell | 3 studies | 46% ± 20% | |
mucus secreting cell | 3 studies | 36% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
stomach | 99% | 1106.83 | 357 / 359 | 94% | 21.87 | 269 / 286 |
pancreas | 97% | 232.52 | 317 / 328 | 84% | 11.28 | 149 / 178 |
intestine | 71% | 544.80 | 688 / 966 | 96% | 23.40 | 507 / 527 |
brain | 79% | 227.90 | 2097 / 2642 | 78% | 12.40 | 551 / 705 |
prostate | 86% | 200.74 | 210 / 245 | 69% | 6.23 | 347 / 502 |
liver | 99% | 388.47 | 223 / 226 | 54% | 4.82 | 220 / 406 |
kidney | 100% | 1112.67 | 89 / 89 | 50% | 5.61 | 453 / 901 |
breast | 67% | 279.49 | 309 / 459 | 77% | 16.10 | 862 / 1118 |
bladder | 62% | 333.00 | 13 / 21 | 64% | 15.33 | 321 / 504 |
lung | 54% | 94.33 | 312 / 578 | 52% | 9.60 | 596 / 1155 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.41 | 1 / 1 |
adrenal gland | 45% | 63.67 | 115 / 258 | 39% | 3.75 | 89 / 230 |
uterus | 44% | 88.77 | 74 / 170 | 25% | 4.47 | 114 / 459 |
esophagus | 16% | 37.17 | 232 / 1445 | 49% | 9.79 | 89 / 183 |
ovary | 54% | 80.07 | 97 / 180 | 7% | 0.89 | 30 / 430 |
skin | 47% | 64.94 | 846 / 1809 | 4% | 0.29 | 20 / 472 |
adipose | 23% | 37.73 | 277 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 7% | 0.52 | 3 / 45 |
eye | 0% | 0 | 0 / 0 | 4% | 0.17 | 3 / 80 |
muscle | 1% | 1.12 | 11 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 1% | 1.07 | 8 / 929 | 0% | 0 | 0 / 0 |
thymus | 0% | 0.11 | 1 / 653 | 0% | 0.03 | 3 / 605 |
spleen | 0% | 0.63 | 1 / 241 | 0% | 0 | 0 / 0 |
heart | 0% | 0.08 | 1 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 0% | 0.18 | 1 / 1335 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006915 | Biological process | apoptotic process |
GO_0042981 | Biological process | regulation of apoptotic process |
GO_0043524 | Biological process | negative regulation of neuron apoptotic process |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_0031490 | Molecular function | chromatin DNA binding |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0051219 | Molecular function | phosphoprotein binding |
GO_0005515 | Molecular function | protein binding |
GO_0003682 | Molecular function | chromatin binding |
Gene name | TOX3 |
Protein name | TOX high mobility group box family member 3 TOX high mobility group box family member 3 (CAG trinucleotide repeat-containing gene F9 protein) (Trinucleotide repeat-containing gene 9 protein) |
Synonyms | CAGF9 TNRC9 |
Description | FUNCTION: Transcriptional coactivator of the p300/CBP-mediated transcription complex. Activates transactivation through cAMP response element (CRE) sites. Protects against cell death by inducing antiapoptotic and repressing pro-apoptotic transcripts. Stimulates transcription from the estrogen-responsive or BCL-2 promoters. Required for depolarization-induced transcription activation of the C-FOS promoter in neurons. Associates with chromatin to the estrogen-responsive C3 promoter region. . |
Accessions | ENST00000568436.1 J3QQQ6 ENST00000219746.14 [O15405-1] H3BTZ9 ENST00000407228.7 [O15405-2] ENST00000563091.1 O15405 |